Engineered immune cells take on lupus in first human trial

NCT ID NCT06892145

Recruiting now Disease control Sponsor: Chongqing Precision Biotech Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jan 08, 2026 · Last updated Jun 15, 2026 · Updated 26 times

Summary

This early-phase study tests a new treatment called MC-1-50 for adults with severe lupus that hasn't responded to standard therapies. The treatment uses a patient's own immune cells, modified to target and destroy faulty immune cells that drive lupus. The main goals are to check safety and find the right dose, while also watching for signs of disease improvement.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital)
RECRUITING

Hefei, Anhui, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
The Second Affiliated Hospital of Zhejiang University School of Medicine
RECRUITING

Hangzhou, Zhejiang, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)